Last reviewed · How we verify
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
Approved treatments
- Lumakras · Amgen
Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth. - Krazati · Bristol-Myers Squibb
Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer treatment landscape brief
- KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer treatment updates RSS
Frequently asked questions about KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
What drugs treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer?
Tracked treatments include Lumakras, Krazati.
What is the treatment for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer?
Standard treatment for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer includes Lumakras, Krazati. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer patent cliff · KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer CI report
- Treatment: Lumakras · Amgen
- Treatment: Krazati · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing